FAQContact Us
  
Patients & Caregivers Healthcare Professionals
 
 
About Vivaglobin®

Vivaglobin® is the first and only FDA-approved subcutaneous (Sub-Q) immunoglobulin (Ig) therapy available for the treatment of patients with primary immunodeficiency (PI).

It’s the therapy option that offers your patients greater freedom and flexibility in receiving their Ig replacement therapy.1-3

Vivaglobin® is:

  • A therapy option to offer your patients with PI
  • As efficacious as intravenous immunoglobulin (IVIg)
  • A choice for active patients whose lifestyles demand flexibility
  • A treatment that patients can administer on their own with your approval

Approved by the FDA in 2006, thousands of US patients have moved beyond their IV therapy to Sub-Q Vivaglobin®. Worldwide, Vivaglobin® has been available for more than 10 years.4

Vivaglobin® is a sterile, ready-to-use, liquid 16% solution of IgG. It is never given intravenously. Instead, Vivaglobin® is infused into the subcutaneous tissue using an ambulatory infusion pump or syringe driver. When administered on a weekly basis, it provides consistent, steady-state serum IgG levels without “wear off” effects.1,2

Vivaglobin® can be administered at a doctor’s office, by home care staff, or by patients, caregivers, or family members. Most adults—and even some children—can easily learn to administer Vivaglobin® at home—often in just 4 to 6 training sessions. 1-3,5

Click here to view the Vivaglobin® self-administration video.

Unencumbered by an IV pole, patients can be ambulatory during administration of Sub-Q Ig, so they experience greater freedom and flexibility. Once patients have learned to properly self-administer their therapy, nursing services may not be needed.

References:

  1. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65-72.
  2. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.J Clin Immunol. 2006;26:265-273.
  3. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.J Allergy Clin Immunol. 2004;114:936-942.
  4. Data on file, CSL Behring 2006.
  5. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177-185.

Next: Benefits of Vivaglobin®